Cayley Russell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cayley Russell has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Jürgen Rehm
Centre for Addiction and Mental Health (CAMH)
15 shared publicationsFarihah Ali
Ontario Node of Canadian Research Initiative in Substance Matters Toronto Ontario Canada
14 shared publications- Jürgen Rehm
Institute for Mental Health Policy Research Centre for Addiction and Mental Health Toronto Canada
14 shared publications - Farihah Ali
Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (CAMH), Toronto, Canada
13 shared publications Sameer Imtiaz
9 shared publications- Sameer Imtiaz
Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Canada
6 shared publications
Latest Publications
- Open Access
Impacts of decriminalization and its subsequent amendment on drug possession incidents and charges in British Columbia, Canada: Interrupted time series analyses (2013–2024)
Background and aims: Decriminalization of personal possession of select illegal drugs was implemented in British Columbia, Canada, for a three‐year period starting 31 January 2023; however, following perceived increases in public drug use and disorder, an amendment introduced on 7 May 2024 rolled back key provisions. We examined the impacts of decriminalization and the subsequent amendment on drug possession incidents and persons charged in drug possession incidents. Design: Uncontrolled and controlled interrupted time series analyses were conducted using generalized additive models (January 2013 to December 2024). Setting: Canada. Cases: Drug possession incidents and persons charged in drug possession incidents in British Columbia and all other Canadian provinces combined. Interventions: Decriminalization (February 2023 to April 2024) allowed adults to possess a combined total of 2.5 g of select illegal drugs. The amendment (May 2024 to December 2024) restricted possession to private residences, communal shelters and harm reduction or addiction treatment facilities. Interventions were coded as dummy measures, with the pre‐decriminalization period set as the reference period. Measurements: Monthly crude rate of drug possession incidents per 100 000 and age‐standardized rate of persons charged in drug possession incidents per 100 000 based on the Uniform Crime Reporting Survey, which is an annual census of criminal incidents reported to federal, provincial and municipal police services in Canada. Results: In the uncontrolled interrupted time series analyses, decriminalization was associated with a decrease [change in the log‐transformed rate (β) = −0.84, 95% confidence interval (CI) = −0.96 to −0.72], while the amendment was not associated with changes (β = −0.12, 95% CI = −0.32 to 0.08), in drug possession incidents in British Columbia. This pattern of findings was also observed in the controlled interrupted time series analyses after differencing all other provinces combined and British Columbia [change in the difference of the log‐transformed rates (β) = 0.85, 95% CI = 0.73–0.97 for decriminalization and β = 0.11, 95% CI = −0.09 to 0.31 for the amendment]. In the uncontrolled interrupted time series analyses, decriminalization was associated with a decrease (β = −0.63, 95% CI = −0.79 to −0.47), while the amendment was not associated with changes (β = −0.27, 95% CI = −0.55 to 0.001), in persons charged in drug possession incidents in British Columbia. This pattern of findings was also observed in the controlled interrupted time series analyses after differencing all other provinces combined and British Columbia (β = 0.61, 95% CI = 0.47–0.76 for decriminalization and β = 0.14, 95% CI = −0.08 to 0.36 for the amendment). Summary: Decriminalization of personal possession of select illegal drugs was associated with decreases in drug possession incidents and persons charged in drug possession incidents in British Columbia relative to other provinces in Canada; the subsequent amendment reversed this progress.
Open AccessImpacts of decriminalization and its subsequent amendment on drug possession incidents and charges in British Columbia, Canada: Interrupted time series analyses (2013–2024)
Background and aims: Decriminalization of personal possession of select illegal drugs was implemented in British Columbia, Canada, for a three‐year period starting 31 January 2023; however, following perceived increases in public drug use and disorder, an amendment introduced on 7 May 2024 rolled back key provisions. We examined the impacts of decriminalization and the subsequent amendment on drug possession incidents and persons charged in drug possession incidents. Design: Uncontrolled and controlled interrupted time series analyses were conducted using generalized additive models (January 2013 to December 2024). Setting: Canada. Cases: Drug possession incidents and persons charged in drug possession incidents in British Columbia and all other Canadian provinces combined. Interventions: Decriminalization (February 2023 to April 2024) allowed adults to possess a combined total of 2.5 g of select illegal drugs. The amendment (May 2024 to December 2024) restricted possession to private residences, communal shelters and harm reduction or addiction treatment facilities. Interventions were coded as dummy measures, with the pre‐decriminalization period set as the reference period. Measurements: Monthly crude rate of drug possession incidents per 100 000 and age‐standardized rate of persons charged in drug possession incidents per 100 000 based on the Uniform Crime Reporting Survey, which is an annual census of criminal incidents reported to federal, provincial and municipal police services in Canada. Results: In the uncontrolled interrupted time series analyses, decriminalization was associated with a decrease [change in the log‐transformed rate (β) = −0.84, 95% confidence interval (CI) = −0.96 to −0.72], while the amendment was not associated with changes (β = −0.12, 95% CI = −0.32 to 0.08), in drug possession incidents in British Columbia. This pattern of findings was also observed in the controlled interrupted time series analyses after differencing all other provinces combined and British Columbia [change in the difference of the log‐transformed rates (β) = 0.85, 95% CI = 0.73–0.97 for decriminalization and β = 0.11, 95% CI = −0.09 to 0.31 for the amendment]. In the uncontrolled interrupted time series analyses, decriminalization was associated with a decrease (β = −0.63, 95% CI = −0.79 to −0.47), while the amendment was not associated with changes (β = −0.27, 95% CI = −0.55 to 0.001), in persons charged in drug possession incidents in British Columbia. This pattern of findings was also observed in the controlled interrupted time series analyses after differencing all other provinces combined and British Columbia (β = 0.61, 95% CI = 0.47–0.76 for decriminalization and β = 0.14, 95% CI = −0.08 to 0.36 for the amendment). Summary: Decriminalization of personal possession of select illegal drugs was associated with decreases in drug possession incidents and persons charged in drug possession incidents in British Columbia relative to other provinces in Canada; the subsequent amendment reversed this progress.
- Open Access
- 20 September 2026
- Published by Taylor & Francis in Policing and Society
- p. 1-20
Policing interactions and outcomes under shifting decriminalization policies in British Columbia: insights from people who use drugs
Criminalisation is recognised worldwide as a driver of direct and indirect harm towards people who use drugs, linked to incarceration, increased overdose risk, and police violence (Werb et al. 2011...
- 20 September 2026
- Published by Taylor & Francis in Policing and Society
- p. 1-20
Open AccessPolicing interactions and outcomes under shifting decriminalization policies in British Columbia: insights from people who use drugs
Criminalisation is recognised worldwide as a driver of direct and indirect harm towards people who use drugs, linked to incarceration, increased overdose risk, and police violence (Werb et al. 2011...
- Open Access
- 9 September 2026
- Published by Springer Nature in Journal of Cannabis Research
Canadian taxation methods for cannabis: an examination of the impact of different tax methods based on legal products sold in Ontario
Background: Ontario, Canada, legalized cannabis for recreational use in October 2018. Taxation consists of a federal base taxation, and provincial additional duties and adjustments. Different tax methods are used for different cannabis products: specific (only) taxation (SO) for processed products (e.g., vapes and edibles), and ad valorem with specific floor taxation (ASF) for unprocessed products (e.g., dried flower and pre-rolls). This study aimed to simulate and compare the impact of the cannabis excise tax methods currently used in Ontario with alternative tax methods to determine which method would be most effective in reducing consumption of high-tetrahydrocannabinol (THC) products. Methods: Using data on 2,568 units of cannabis products sold legally in Ontario in March 2022, we explored the structure of taxes and prices per mg of THC of these products under the current cannabis excise tax methods: Compare ASF and SO taxationto alternative simulated tax methods, bases, and rates. Results: Our study found four key insights. (1) The currently used ASF taxation, based on flower weight, created a lower tax per mg of THC for high THC products. (2) THC-based SO taxation created a greater percentage of excise tax on high THC products. (3) Compared to other tax methods, SO taxation produced the greatest average excise tax per mg of THC for all THC-concentration products and higher tax rates per mg of THC for high-THC products, and reduced the tax and price gaps between the lowest and the highest THC-concentration categories. (4) SO taxation, however, produces much lower tax per mg of THC for the lowest THC products, such as youth-friendly edible cannabis products. Conclusions: The Ontario government could consider changing from applying the complex cannabis excise tax system to a single excise tax method to all types of cannabis products, either utilizing the SO taxation based on total THC content to reduce the consumption of the high THC-concentration products, or the mixed ad valorem and specific taxation based on total THC content, with a high proportion of the specific tax, to reduce consumption of youth-friendly edible-type cannabis products in addition to reducing consumption of high THC products in general.
- 9 September 2026
- Published by Springer Nature in Journal of Cannabis Research
Open AccessCanadian taxation methods for cannabis: an examination of the impact of different tax methods based on legal products sold in Ontario
Background: Ontario, Canada, legalized cannabis for recreational use in October 2018. Taxation consists of a federal base taxation, and provincial additional duties and adjustments. Different tax methods are used for different cannabis products: specific (only) taxation (SO) for processed products (e.g., vapes and edibles), and ad valorem with specific floor taxation (ASF) for unprocessed products (e.g., dried flower and pre-rolls). This study aimed to simulate and compare the impact of the cannabis excise tax methods currently used in Ontario with alternative tax methods to determine which method would be most effective in reducing consumption of high-tetrahydrocannabinol (THC) products. Methods: Using data on 2,568 units of cannabis products sold legally in Ontario in March 2022, we explored the structure of taxes and prices per mg of THC of these products under the current cannabis excise tax methods: Compare ASF and SO taxationto alternative simulated tax methods, bases, and rates. Results: Our study found four key insights. (1) The currently used ASF taxation, based on flower weight, created a lower tax per mg of THC for high THC products. (2) THC-based SO taxation created a greater percentage of excise tax on high THC products. (3) Compared to other tax methods, SO taxation produced the greatest average excise tax per mg of THC for all THC-concentration products and higher tax rates per mg of THC for high-THC products, and reduced the tax and price gaps between the lowest and the highest THC-concentration categories. (4) SO taxation, however, produces much lower tax per mg of THC for the lowest THC products, such as youth-friendly edible cannabis products. Conclusions: The Ontario government could consider changing from applying the complex cannabis excise tax system to a single excise tax method to all types of cannabis products, either utilizing the SO taxation based on total THC content to reduce the consumption of the high THC-concentration products, or the mixed ad valorem and specific taxation based on total THC content, with a high proportion of the specific tax, to reduce consumption of youth-friendly edible-type cannabis products in addition to reducing consumption of high THC products in general.
- Open Access
- 10 August 2026
- Published by Wolters Kluwer Health in Canadian Journal of Addiction
- Vol. 17 (3) , 59-65
Recent Trends in Overdose Deaths and Corresponding Illegal Drug Identifications Across Canadian Provinces
Objectives: Declines in drug poisoning deaths have been observed in Canada: it remains unclear whether these reflect sustained trends or temporary fluctuations, or whether they are influenced by the unregulated drug supply. To better understand these dynamics, this study examined temporal patterns in drug poisoning deaths alongside trends in drug identifications from law-enforcement–seized samples. Methods: Data were collected on opioid and stimulant poisoning deaths, as well as fentanyl, cocaine, and methamphetamine identifications. Province-specific trends were analyzed using joinpoint regression, with average quarterly percentage changes (AQPCs) and average annual percentage changes (AAPCs) calculated for 2023 to 2024. Results: Between Q1 2023 and Q4 2024, trends in drug poisoning deaths and drug identifications varied across provinces. Opioid poisoning deaths declined in Alberta, Saskatchewan, and Ontario, but increased in Quebec and New Brunswick. Stimulant poisoning deaths decreased in British Columbia, but rose in Manitoba, New Brunswick, and Nova Scotia. Analysis of seized drug samples showed parallel changes in the unregulated supply: fentanyl identifications decreased in British Columbia, Alberta, and Ontario; cocaine identifications declined in British Columbia but increased in Manitoba, Quebec, and New Brunswick; and methamphetamine identifications decreased in British Columbia, Alberta, Saskatchewan, Ontario, and New Brunswick. Conclusions: Our findings underscore pronounced regional heterogeneity in drug-related harms across Canada, likely shaped by differences in enforcement, drug markets and use patterns, service coverage, and policy context. Continued province-specific surveillance is essential for mitigating emerging risks and informing evidence-based policy. Objectifs: On observe au Canada une baisse du nombre de décès par intoxication liés à la consommation de drogues illicites: il est difficile de déterminer si cette baisse reflète des tendances durables ou des fluctuations temporaires, ou si elle est influencée par l’offre non réglementée de drogues. Afin de mieux comprendre ces dynamiques, cette étude a examiné les tendances temporelles des décès par intoxication liés à la consommation de drogues illicites parallèlement aux tendances observées dans l’identification des substances à partir d’échantillons saisis par les forces de l’ordre. Méthodes: Des données ont été recueillies sur les décès par intoxication aux opioïdes et aux stimulants, ainsi que sur les identifications de fentanyl, de cocaïne et de méthamphétamine. Les tendances spécifiques à chaque province ont été analysées à l’aide d’une régression par points de jonction, avec des variations trimestrielles moyennes en pourcentage (VTMP) et des variations annuelles moyennes en pourcentage (VAMP) calculées pour la période 2023-2024. Résultats: Entre le premier trimestre 2023 et le quatrième trimestre 2024, les tendances concernant les décès par intoxication liés à la consommation de drogues illicites et l’identification des substances ont varié d’une province à l’autre. Les décès par intoxication aux opioïdes ont diminué en Alberta, en Saskatchewan et en Ontario, mais ont augmenté au Québec et au Nouveau-Brunswick. Les décès par intoxication aux stimulants ont diminué en Colombie-Britannique, mais ont augmenté au Manitoba, au Nouveau-Brunswick et en Nouvelle-Écosse. L’analyse des échantillons de drogues saisis a révélé des changements parallèles dans l’offre non réglementée : les identifications de fentanyl ont diminué en Colombie-Britannique, en Alberta et en Ontario ; les identifications de cocaïne ont diminué en Colombie-Britannique, mais ont augmenté au Manitoba, au Québec et au Nouveau-Brunswick ; et les identifications de méthamphétamine ont diminué en Colombie-Britannique, en Alberta, en Saskatchewan, en Ontario et au Nouveau-Brunswick. Conclusions: Nos résultats soulignent une hétérogénéité régionale marquée des effets néfastes liés à la consommation de drogues à travers le Canada, probablement influencée par des différences en matière d’application de la loi, de marchés de la drogue et de modes de consommation, de couverture des services et de contexte politique. Une surveillance continue spécifique à chaque province est essentielle pour atténuer les risques émergents et éclairer l'élaboration de politiques fondées sur des données probantes.
- 10 August 2026
- Published by Wolters Kluwer Health in Canadian Journal of Addiction
- Vol. 17 (3) , 59-65
Open AccessRecent Trends in Overdose Deaths and Corresponding Illegal Drug Identifications Across Canadian Provinces
Objectives: Declines in drug poisoning deaths have been observed in Canada: it remains unclear whether these reflect sustained trends or temporary fluctuations, or whether they are influenced by the unregulated drug supply. To better understand these dynamics, this study examined temporal patterns in drug poisoning deaths alongside trends in drug identifications from law-enforcement–seized samples. Methods: Data were collected on opioid and stimulant poisoning deaths, as well as fentanyl, cocaine, and methamphetamine identifications. Province-specific trends were analyzed using joinpoint regression, with average quarterly percentage changes (AQPCs) and average annual percentage changes (AAPCs) calculated for 2023 to 2024. Results: Between Q1 2023 and Q4 2024, trends in drug poisoning deaths and drug identifications varied across provinces. Opioid poisoning deaths declined in Alberta, Saskatchewan, and Ontario, but increased in Quebec and New Brunswick. Stimulant poisoning deaths decreased in British Columbia, but rose in Manitoba, New Brunswick, and Nova Scotia. Analysis of seized drug samples showed parallel changes in the unregulated supply: fentanyl identifications decreased in British Columbia, Alberta, and Ontario; cocaine identifications declined in British Columbia but increased in Manitoba, Quebec, and New Brunswick; and methamphetamine identifications decreased in British Columbia, Alberta, Saskatchewan, Ontario, and New Brunswick. Conclusions: Our findings underscore pronounced regional heterogeneity in drug-related harms across Canada, likely shaped by differences in enforcement, drug markets and use patterns, service coverage, and policy context. Continued province-specific surveillance is essential for mitigating emerging risks and informing evidence-based policy. Objectifs: On observe au Canada une baisse du nombre de décès par intoxication liés à la consommation de drogues illicites: il est difficile de déterminer si cette baisse reflète des tendances durables ou des fluctuations temporaires, ou si elle est influencée par l’offre non réglementée de drogues. Afin de mieux comprendre ces dynamiques, cette étude a examiné les tendances temporelles des décès par intoxication liés à la consommation de drogues illicites parallèlement aux tendances observées dans l’identification des substances à partir d’échantillons saisis par les forces de l’ordre. Méthodes: Des données ont été recueillies sur les décès par intoxication aux opioïdes et aux stimulants, ainsi que sur les identifications de fentanyl, de cocaïne et de méthamphétamine. Les tendances spécifiques à chaque province ont été analysées à l’aide d’une régression par points de jonction, avec des variations trimestrielles moyennes en pourcentage (VTMP) et des variations annuelles moyennes en pourcentage (VAMP) calculées pour la période 2023-2024. Résultats: Entre le premier trimestre 2023 et le quatrième trimestre 2024, les tendances concernant les décès par intoxication liés à la consommation de drogues illicites et l’identification des substances ont varié d’une province à l’autre. Les décès par intoxication aux opioïdes ont diminué en Alberta, en Saskatchewan et en Ontario, mais ont augmenté au Québec et au Nouveau-Brunswick. Les décès par intoxication aux stimulants ont diminué en Colombie-Britannique, mais ont augmenté au Manitoba, au Nouveau-Brunswick et en Nouvelle-Écosse. L’analyse des échantillons de drogues saisis a révélé des changements parallèles dans l’offre non réglementée : les identifications de fentanyl ont diminué en Colombie-Britannique, en Alberta et en Ontario ; les identifications de cocaïne ont diminué en Colombie-Britannique, mais ont augmenté au Manitoba, au Québec et au Nouveau-Brunswick ; et les identifications de méthamphétamine ont diminué en Colombie-Britannique, en Alberta, en Saskatchewan, en Ontario et au Nouveau-Brunswick. Conclusions: Nos résultats soulignent une hétérogénéité régionale marquée des effets néfastes liés à la consommation de drogues à travers le Canada, probablement influencée par des différences en matière d’application de la loi, de marchés de la drogue et de modes de consommation, de couverture des services et de contexte politique. Une surveillance continue spécifique à chaque province est essentielle pour atténuer les risques émergents et éclairer l'élaboration de politiques fondées sur des données probantes.
- 26 July 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 71 (5) , 108526
The Impact of British Columbia’s Drug Decriminalization Policy on Police-Reported Drug Possession Seizures
- 26 July 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 71 (5) , 108526
The Impact of British Columbia’s Drug Decriminalization Policy on Police-Reported Drug Possession Seizures
- Open Access
- 22 July 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 156
Implementation factors shaping British Columbia’s drug decriminalization pilot: A systematic review with narrative synthesis
- 22 July 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 156
Open AccessImplementation factors shaping British Columbia’s drug decriminalization pilot: A systematic review with narrative synthesis
- Open Access
- 9 April 2026
- Published by Springer Nature in Canadian Journal of Public Health
Clarifying the evidence and implications of prioritizing extended-release buprenorphine for opioid agonist treatment in Canada’s federal correctional system
Correctional Service Canada (CSC) recently revised its opioid agonist treatment (OAT) policy, designating extended-release injectable buprenorphine (XR-BUP; Sublocade) as the first-line treatment for opioid use disorder (OUD) in Canadian federal corrections. Methadone is now a second-line option, and buprenorphine/naloxone is no longer available, raising concerns regarding access, clinical autonomy, and equivalence of care. CSC cited clinical evidence suggesting advantages of XR-BUP, including reduced diversion, simplified dosing, and superior efficacy. One of the primary sources referenced for the policy revisions was a systematic review examining the feasibility and effectiveness of XR-BUP among correctional populations. Here, we clarify the findings and limitations of this review, and examine key implications of CSC’s policy revision. While available evidence suggests that XR-BUP is a beneficial OAT option for incarcerated individuals, the literature remains preliminary, heterogeneous, and methodologically limited. It currently does not robustly support the use of XR-BUP as an exclusive replacement for established first-line OAT options. Restricting access to evidence-based OAT options among correctional populations risks undermining patient-centered care, continuity of treatment, and alignment with general clinical guidelines. Ideally, XR-BUP should be offered as a valuable addition, while preserving access to the full range of evidence-based OAT options.
- 9 April 2026
- Published by Springer Nature in Canadian Journal of Public Health
Open AccessClarifying the evidence and implications of prioritizing extended-release buprenorphine for opioid agonist treatment in Canada’s federal correctional system
Correctional Service Canada (CSC) recently revised its opioid agonist treatment (OAT) policy, designating extended-release injectable buprenorphine (XR-BUP; Sublocade) as the first-line treatment for opioid use disorder (OUD) in Canadian federal corrections. Methadone is now a second-line option, and buprenorphine/naloxone is no longer available, raising concerns regarding access, clinical autonomy, and equivalence of care. CSC cited clinical evidence suggesting advantages of XR-BUP, including reduced diversion, simplified dosing, and superior efficacy. One of the primary sources referenced for the policy revisions was a systematic review examining the feasibility and effectiveness of XR-BUP among correctional populations. Here, we clarify the findings and limitations of this review, and examine key implications of CSC’s policy revision. While available evidence suggests that XR-BUP is a beneficial OAT option for incarcerated individuals, the literature remains preliminary, heterogeneous, and methodologically limited. It currently does not robustly support the use of XR-BUP as an exclusive replacement for established first-line OAT options. Restricting access to evidence-based OAT options among correctional populations risks undermining patient-centered care, continuity of treatment, and alignment with general clinical guidelines. Ideally, XR-BUP should be offered as a valuable addition, while preserving access to the full range of evidence-based OAT options.
- Top Cited PapersOpen Access
- 25 February 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 151, 105211
Doubts and disconnection: Police reflections on drug decriminalization in British Columbia in the first year of implementation
- 25 February 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 151, 105211
Top Cited PapersOpen AccessDoubts and disconnection: Police reflections on drug decriminalization in British Columbia in the first year of implementation
- Open Access
- 27 January 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (2) , 286-295
Drug harms in Canada: A multi-criteria decision analysis
Background: Multi-criteria decision analysis (MCDA) has been used to quantify drug harms in the United Kingdom, the European Union, Australia, and New Zealand. This paper presents the result of an MCDA conducted in Canada, with the aim of informing Canadian drug policy and contributing to public understanding of drugs’ relative harms. Methods: A panel composed of 20 experts from six provinces determined 16 drugs to evaluate on 16 dimensions of harm (ten representing harm to people who use the drug; six representing harm to others). At a two-day decision conference, the panel scored each drug on a scale of 0–100 for each harm criterion, then weighted the relative importance of each criterion. Results: This analysis of drug harms in Canada found that alcohol causes the most harm overall, with a cumulative weighted score of 79. It was followed by tobacco (45), nonprescription opioids (33), cocaine (19), methamphetamine (19), and cannabis (15). The finding that alcohol causes the most harm is consistent with the results of previous MCDA drug harm studies. Conclusion: These harm scores express population-level harm rather than individual-level “harmfulness.” They reflect not only a drug’s pharmacological risk profile but also the current policy context in Canada. The high score for alcohol underscores a failure to adopt policies to address alcohol-related harms, despite the known health harms and the existence of proven policy measures. More broadly, when developing drug policies, governments should consider the harm—both individual and societal—caused by drugs and by the laws and regulations that govern them.
- 27 January 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (2) , 286-295
Open AccessDrug harms in Canada: A multi-criteria decision analysis
Background: Multi-criteria decision analysis (MCDA) has been used to quantify drug harms in the United Kingdom, the European Union, Australia, and New Zealand. This paper presents the result of an MCDA conducted in Canada, with the aim of informing Canadian drug policy and contributing to public understanding of drugs’ relative harms. Methods: A panel composed of 20 experts from six provinces determined 16 drugs to evaluate on 16 dimensions of harm (ten representing harm to people who use the drug; six representing harm to others). At a two-day decision conference, the panel scored each drug on a scale of 0–100 for each harm criterion, then weighted the relative importance of each criterion. Results: This analysis of drug harms in Canada found that alcohol causes the most harm overall, with a cumulative weighted score of 79. It was followed by tobacco (45), nonprescription opioids (33), cocaine (19), methamphetamine (19), and cannabis (15). The finding that alcohol causes the most harm is consistent with the results of previous MCDA drug harm studies. Conclusion: These harm scores express population-level harm rather than individual-level “harmfulness.” They reflect not only a drug’s pharmacological risk profile but also the current policy context in Canada. The high score for alcohol underscores a failure to adopt policies to address alcohol-related harms, despite the known health harms and the existence of proven policy measures. More broadly, when developing drug policies, governments should consider the harm—both individual and societal—caused by drugs and by the laws and regulations that govern them.
- Open Access
- 2 January 2026
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 52 (1) , 52-63
Shifting views on decriminalization in British Columbia: insights from public opinion polling, 2024–2025
In January 2023, British Columbia (BC) became the first jurisdiction in Canada to implement a three-year exemption under the federal Controlled Drugs and Substances Act, decriminalizing possession ...
- 2 January 2026
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 52 (1) , 52-63
Open AccessShifting views on decriminalization in British Columbia: insights from public opinion polling, 2024–2025
In January 2023, British Columbia (BC) became the first jurisdiction in Canada to implement a three-year exemption under the federal Controlled Drugs and Substances Act, decriminalizing possession ...